Spatiotemporal Staging of the HIV-1 Preintegration complex
HIV-1 预整合复合体的时空分期
基本信息
- 批准号:10548553
- 负责人:
- 金额:$ 65.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-20 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS/HIV problemAcuteAffectAnti-Retroviral AgentsBiochemicalBiochemistryBiological AssayBiologyCapsidCell NucleusCellsChromosomesComplexCoupledCrude ExtractsCytoplasmDNADNA IntegrationDNA biosynthesisDataDevelopmentDisease ManagementDrug resistanceEnzymesFaceGenomeHIVHIV InfectionsHIV-1HIV-1 integraseHourIn VitroInfectionIntegraseIntegrase InhibitorsIntegration Host FactorsKineticsKnowledgeLifeLinkMeasuresMediatingMetabolicModelingMonitorNuclearNuclear ExtractNuclear Pore ComplexPersonsPharmaceutical PreparationsPlayPositioning AttributeRNAReagentRegimenResearchReverse TranscriptionRoleStagingT-LymphocyteTestingTimeTranscription ProcessViralVirusVirus Integrationantiretroviral therapybasedrug developmentds-DNAimprovedin vitro activityinhibitorinsertion/deletion mutationmutantneuropsychiatrynovelnovel strategiespreservationspatiotemporaltime usetoolviral DNAviral RNA
项目摘要
ABSTRACT
Approximately 1.2 million people in the US and ~40 million people worldwide are infected with HIV. In
spite of significant progress in HIV/AIDS research, anti-retroviral therapy (ART) remains the only treatment
option available for HIV-1 infection. ART has been highly effective in controlling the virus and making HIV
infection a manageable disease. Specifically, inhibitors of HIV-1 Integrase (IN) are used as the preferred drugs
in the current ART regimens. However, these inhibitors continue to face drug resistance and there is growing
concern of the adverse metabolic and neuropsychiatric effects of these inhibitors. Thus, there is a need for the
development of new and improved IN inhibitors for effective and long-term control HIV-1 infection. Such effort
is critically dependent on a better understanding of the mechanisms of HIV-1 integration. It is important to note
that studies of the preintegration complex (PIC) extracted from acutely infected cells have been instrumental in
defining the mechanisms of HIV-1 integration. Furthermore, PIC studies have played a central role in the
development of currently used IN inhibitors. Therefore, our proposal to define the mechanism of HIV-1 PIC
formation will generate new knowledge to promote the development of new and improved IN-based therapies.
Retroviral replication is dependent on the essential steps of reverse transcription (RTN) and integration.
In the case of HIV, the RNA genome is reverse transcribed into a DNA copy by the reverse transcription
complex (RTC). Then, the RTC transitions into a PIC by an unknown mechanism and undefined time. The PIC,
containing the viral DNA, the IN enzyme, and other viral/host factors, carries out integration. The prevailing
view is that HIV-1 RTN is completed in the cytoplasm and/or at the nuclear pore complex (NPC). Thus, nuclear
entry of the PIC is necessary to carry out HIV-1 DNA integration into the host chromosomes. However, new
evidence suggest that the intact HIV-1 capsid enters the nucleus and RTN is completed after the nuclear entry
step. A nuclear completion of RTN creates key knowledge gaps in our current understanding of the PIC. We
hypothesize that functional HIV-1 PICs are formed prior to the completion of RTN and nuclear entry protects
the integrity of the PIC-viral DNA. This proposal will test this hypothesis through three specific aims: Aim 1 will
define the link between the timing of functional PIC formation relative to RTN completion, Aim 2 will assess the
role of nuclear entry on PIC function, and Aim 3 will determine the spatiotemporal transition of the RTC to a
PIC. For these aims, we have developed a novel approach of quantifying PIC-specific integration activity and
measuring HIV-1 core-mediated DNA integration, coupled with the blockade of viral nuclear entry and time of
inhibitor addition assays. Together, these studies will define the mechanistic and kinetic link between HIV-1
RTN and PIC function. Most importantly, our team is uniquely qualified to successfully complete this timely
R01-project, since we have the expertise, reagents, and the tools required to study PIC biochemistry (Dash),
Capsid biology (Aiken), Nuclear entry (Campbell), and Integration (Engelman and Craigie).
摘要
美国约有120万人,全世界约有4000万人感染艾滋病毒。在
尽管艾滋病研究取得了重大进展,但抗逆转录病毒疗法仍然是唯一的治疗方法
HIV-1感染者的选择。抗逆转录病毒疗法在控制病毒和使艾滋病毒
感染是一种可以控制的疾病。具体地,HIV-1整合酶(IN)的抑制剂被用作优选药物
在目前的ART治疗方案中。然而,这些抑制剂继续面临耐药性,
这些抑制剂的不良代谢和神经精神作用的关注。因此,需要
开发新的和改进的IN抑制剂,用于有效和长期控制HIV-1感染。这种努力
关键取决于对HIV-1整合机制的更好理解。重要的是要注意
从急性感染细胞中提取的整合前复合物(PIC)的研究有助于
定义HIV-1整合的机制。此外,事先知情同意研究在
目前使用的IN抑制剂的开发。因此,我们建议定义HIV-1 PIC的机制,
形成将产生新的知识,以促进新的和改进的基于IN的疗法的发展。
逆转录病毒复制依赖于逆转录(RTN)和整合的基本步骤。
在HIV的情况下,RNA基因组通过逆转录被逆转录成DNA拷贝,
复合物(RTC)。然后,RTC通过未知的机制和未定义的时间过渡到PIC。PIC,
含有病毒DNA、IN酶和其他病毒/宿主因子的细胞进行整合。现行
HIV-1 RTN在细胞质和/或核孔复合体(NPC)中完成。因此,核
PIC的进入是进行HIV-1 DNA整合到宿主染色体中所必需的。但新
有证据表明,完整的HIV-1衣壳进入细胞核,RTN在进入细胞核后完成
步RTN的核完成在我们目前对PIC的理解中造成了关键的知识空白。我们
假设功能性HIV-1 PIC在RTN完成之前形成,核进入保护了
PIC病毒DNA的完整性。本提案将通过三个具体目标来检验这一假设:
定义功能PIC形成时间与RTN完成时间之间的联系,目标2将评估
核进入对PIC功能的作用,目标3将决定RTC到PIC功能的时空转变
PIC.为了实现这些目标,我们开发了一种新的方法来量化PIC特异性整合活性,
测量HIV-1核心介导的DNA整合,加上病毒核进入的阻断和
抑制剂添加测定。总之,这些研究将确定HIV-1之间的机制和动力学联系,
RTN和PIC功能。最重要的是,我们的团队是唯一有资格成功完成这一及时
R 01-项目,因为我们拥有研究PIC生物化学所需的专业知识,试剂和工具(Dash),
衣壳生物学(Aiken)、核进入(坎贝尔)和整合(Engelman和Craigie)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chandravanu Dash其他文献
Chandravanu Dash的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chandravanu Dash', 18)}}的其他基金
Role of GRIN2 in ART and SUD associated neurological deficits.
GRIN2 在 ART 和 SUD 相关神经功能缺损中的作用。
- 批准号:
10561195 - 财政年份:2022
- 资助金额:
$ 65.88万 - 项目类别:
Spatiotemporal Staging of the HIV-1 Preintegration complex
HIV-1 预整合复合体的时空分期
- 批准号:
10625528 - 财政年份:2022
- 资助金额:
$ 65.88万 - 项目类别:
Role of GRIN2 in ART and SUD associated neurological deficits.
GRIN2 在 ART 和 SUD 相关神经功能缺损中的作用。
- 批准号:
10701055 - 财政年份:2022
- 资助金额:
$ 65.88万 - 项目类别:
Enhancing Virology Training of Underrepresented Minority Students through Summer Research
通过暑期研究加强对代表性不足的少数民族学生的病毒学培训
- 批准号:
10313298 - 财政年份:2021
- 资助金额:
$ 65.88万 - 项目类别:
Enhancing Virology Training of Underrepresented Minority Students through Summer Research
通过暑期研究加强对代表性不足的少数民族学生的病毒学培训
- 批准号:
10669049 - 财政年份:2021
- 资助金额:
$ 65.88万 - 项目类别:
Enhancing Virology Training of Underrepresented Minority Students through Summer Research
通过暑期研究加强对代表性不足的少数民族学生的病毒学培训
- 批准号:
10458092 - 财政年份:2021
- 资助金额:
$ 65.88万 - 项目类别:
Role of the Viral Capsid in HIV-1 Integration
病毒衣壳在 HIV-1 整合中的作用
- 批准号:
10436824 - 财政年份:2019
- 资助金额:
$ 65.88万 - 项目类别:
Role of the Viral Capsid in HIV-1 Integration
病毒衣壳在 HIV-1 整合中的作用
- 批准号:
9977928 - 财政年份:2019
- 资助金额:
$ 65.88万 - 项目类别:
Role of the Viral Capsid in HIV-1 Integration
病毒衣壳在 HIV-1 整合中的作用
- 批准号:
10199944 - 财政年份:2019
- 资助金额:
$ 65.88万 - 项目类别:
Cocaine downregulates anti-HIV microRNAs in CD4+ T cells
可卡因下调 CD4 T 细胞中的抗 HIV microRNA
- 批准号:
8329914 - 财政年份:2012
- 资助金额:
$ 65.88万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 65.88万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 65.88万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 65.88万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 65.88万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 65.88万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 65.88万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 65.88万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 65.88万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 65.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 65.88万 - 项目类别:
Operating Grants